MiCheck® Prostate is now available in Australia and the US

Expert Opinion on Need for Biomarker Panels in Biopsy Decisions

Neal D. Shore, MD, FACS presented abstract 229 regarding the current need for a more accurate diagnostic test to identify patients for prostate biopsy at the 2022 ASCO Genitourinary Cancers Symposium.

The Unmet Need for a Biomarker to Support Imaging and Prevent Unnecessary Biopsies

Professor Mark Emberton OBE, University College London, on his study that aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (PCa) and develop a new image-based method with biomarkers like the MiCheck® Prostate for diagnosing high/low risk PCa in men.

MiCheck® Prostate

MiCheck® Prostate is intended for use as an aid to clinicians in the decision to proceed to prostate biopsy in patients with an elevated PSA.

  • MiCheck® Prostate provides a percentage risk of aggressive prostate cancer.
  • MiCheck® Prostate has demonstrated the ability to differentiate aggressive from non-aggressive cancer and no cancer.
  • MiCheck® Prostate demonstrates a compelling advantage in specificity over existing products, outperforming the benchmark PSA test as well as other tests such as % free PSA and the Prostate Health Index (PHI) in a head-to-head comparison.
  • The lack of specificity of other tests has led to criticism due to the resulting unnecessary biopsies. MiCheck® Prostate helps fill this substantial unmet clinical need by allowing a reduction in number of biopsies while minimising the risk of missing out aggressive prostate cancer cases.
MiCheck® Prostate also offers:

Ease of use – blood collection made at the same time as the blood draw for a PSA test.

No interruption to the clinician’s current workflow.

Clear clinical utility – single page well-defined report to help the clinician determine whether the patient needs a biopsy or future follow-up in the coming months.

Timely delivery of results – ready for the patient’s next visit to the clinician.

Dominant health economics in comparison to standard of care.

✔ Early availability as a LDT through a CLIA certified high complexity laboratory.

Achievements

N

2022

N

US CLIA Lab Certification

N

2021

N

Minomic International Limited establishes commercial partnership with 20/20 GeneSystems to offer MiCheck® Prostate in the USA

N

Minomic enters into collaboration with GloriousMed to introduce MiCheck® Prostate into China

N

Laboratory Developed MiCheck® Prostate Cancer Test Roll-out

N

2020

N

MiCheck® Pancreatic Cancer Study Commenced

N

2018

N

Completed MiCheck® Prostate Cancer Prospective Trial

N

2016

N

Awarded Accelerating Commercialization Grant to Further Product Development

N

2014

N

Clinical Validation Studies for MiCheck® Prostate Cancer Commenced

Find Out More Information

  • About our highly effective prostate cancer blood test >More
  • About how your company and Minomic could partner to deliver better prostate cancer diagnostics >More 

13 + 14 =